Below you can find an overview of current trials in Australia and New Zealand:
Psilocybin trials
Study Type |
Trial ID or DOI |
Condition |
Year Registered |
Ethics Status |
Status |
Year Complete |
Location |
Sponsor |
n |
Masking |
Intervention |
Control |
Phase 2 |
ACTRN12621001097831 |
Treatment-Resistant Depression |
2021 |
Approved |
Not yet recruiting |
Ongoing |
VIC |
Swinburne University |
15 |
Open |
25mg psilocybin with psychotherapy |
None |
Phase 2 |
ACTRN12621001358831 |
Generalised Anxiety Disorder |
2021 |
Approved |
Not yet recruiting |
Ongoing |
VIC |
Monash University |
72 |
Quadruple |
25 or 30mg psilocybin with psychotherapy |
control with psychotherapy |
Phase 2 |
ACTRN12619001225101 |
Depression and anxiety (in life-threatening illness) |
2019 |
Approved |
Recruiting |
Ongoing |
VIC |
St Vincent’s Hospital Melbourne |
40 |
Quadruple |
25mg psilocybin with psychotherapy |
placebo with psychotherapy |
Phase 1 |
ACTRN12621000560897 |
Functional Neurological Disorder |
2021 |
Approved |
Not yet recruiting |
Ongoing |
VIC |
Austin Health |
22 |
Open |
5, 10 then 15mg psilocybin with physiotherapy |
None |
Phase 1 |
ACTRN12621000578808 |
Functional Neurological Disorder |
2021 |
Approved |
Not yet recruiting |
Ongoing |
VIC |
Austin Health |
15 |
Open |
0.08-0.1mg/kg psilocybin with physiotherapy |
None |
Phase 1 |
ACTRN12621001375842 |
Mechanism |
2021 |
Approved |
Not yet recruiting |
Ongoing |
VIC |
Monash University |
60 |
Open |
19mg psilocybin with meditation |
19mg psilocybin without meditation |
Phase 1 |
No ID yet |
Mechanism |
2021 |
Approved |
Recruiting |
Ongoing |
VIC |
Monarch Mental Health |
100 |
- |
n = 100 for psilocybin arm |
n = 100 for MDMA arm |
Phase 3 / Phase 2 |
ACTRN12622000883718p |
Brain Activity in Healthy Adults |
2022 |
Other |
Not yet recruiting |
Ongoing |
VIC |
TMS Clinics Australia |
200 |
Open |
25, 30, 35mg psilocybin; or 80 or 120mg MDMA |
None |
Phase 1 |
ACTRN12621001375842 |
Brain Activity in Healthy Adults |
2021 |
Approved |
Not yet recruiting |
Ongoing |
VIC |
Monash University |
60 |
Open |
19mg psilocybin |
Meditation verses No Meditation |
Phase 1 |
ACTRN12622000463774 |
Methamphetamine Use Disorder |
2022 |
Approved |
Not yet recruiting |
Ongoing |
NSW |
St Vincent’s Hospital |
15 |
Open |
Three sessions of 25mg psilocybin with Psychotherapy |
None |
MDMA trials
Study Type |
Trial ID or DOI |
Condition |
Year Registered |
Ethics Status |
Status |
Year Complete |
Location |
Sponsor |
n |
Masking |
Intervention |
Control |
Phase 2 |
ACTRN12619001334190 |
Late-stage cancer patients, mood and anxiety |
2019 |
Approved |
Not yet recruiting |
Ongoing |
NZ |
University of Otago |
32 |
Quadruple |
120mg MDMA (supplemented 60mg) with psychotherapy |
None |
Phase 1/2 |
ACTRN12621001078842 |
PTSD |
2021 |
Approved |
Not yet recruiting |
Ongoing |
WA |
Edith Cowan University |
4 |
Open |
80 or 120mg MDMA (supplemented 40 or 60mg) with psychotherapy |
None |
Phase 1 |
No ID yet |
Mechanism |
2021 |
Approved |
Recruiting |
Ongoing |
VIC |
Monarch Mental Health |
100 |
- |
n = 100 for MDMA arm |
n = 100 for psilocybin arm |
Phase 0 |
ACTRN12613000685718 |
Tinnitus |
2013 |
Approved |
Complete |
2017 |
NZ |
The University of Auckland |
40 |
Quadruple |
30 or 70mg MDMA |
Placebo |
Observational |
ACTRN12620001068954 |
Attitudes of psychotherapists towards MDMA-assisted psychotherapy |
2020 |
Approved |
Recruiting |
Ongoing |
NSW |
University of Sydney |
200 |
Triple |
MDMA-assisted psychotherapy questionnaire |
Fabricated drug-assisted psychotherapy questionnaire |
Phase 3 / Phase 2 |
ACTRN12622000883718p |
Brain Activity in Healthy Adults |
2022 |
Other |
Not yet recruiting |
Ongoing |
VIC |
TMS Clinics Australia |
200 |
Open |
80 or 120mg MDMA; or 25, 30, 35mg psilocybin |
None |
LSD trials
Study Type |
Trial ID or DOI |
Condition |
Year Registered |
Ethics Status |
Status |
Year Complete |
Location |
Sponsor |
n |
Masking |
Intervention |
Control |
Phase 1 |
ACTRN12621000436875 |
Microdose, mechanism and creativity |
2021 |
Approved |
Not yet recruiting |
Ongoing |
NZ |
The University of Auckland |
80 |
Triple |
10ug LSD |
Placebo |
Ibogaine trials
Study Type |
Trial ID or DOI |
Condition |
Year Registered |
Ethics Status |
Status |
Year Complete |
Location |
Sponsor |
n |
Masking |
Intervention |
Control |
Phase 2 |
10.1080/00952990.2017.1310218 |
Addiction, opioid |
2012 |
Approved |
Complete |
2015 |
NZ |
University of Otago |
14 |
Open |
200mg ibogaine (supplementary dose 400-600mg) |
None |
Phase 1 |
ACTRN12613000324718 |
Mechanism |
2013 |
Approved |
Complete |
2013 |
NZ |
University of Otago |
24 |
Open |
20mg ibogaine |
Placebo; or DXM control |
Observational (Follow Up) |
10.1080/00952990.2017.1310218 |
Addiction, opioid |
2015 |
Approved |
Complete |
2016 |
NZ |
University of Otago |
14 |
Open |
Addiction and depression severity at 12 month follow up post-ibogaine treatment |
None |
DMT
Study Type |
Trial ID or DOI |
Condition |
Year Registered |
Ethics Status |
Status |
Year Complete |
Location |
Sponsor |
n |
Masking |
Intervention |
Control |
Phase 1 |
ACTRN12622000851763 |
Healthy Adults |
2022 |
Approved |
Not yet recruiting |
Ongoing |
NZ |
Viridia Life Sciences Australia |
48 |
Open |
VLS-01 Single-Ascending Dose |
Intravenous vs Buccal Administration |
Iprocin (4-OH-DiPT)
Study Type |
Trial ID or DOI |
Condition |
Year Registered |
Ethics Status |
Status |
Year Complete |
Location |
Sponsor |
n |
Masking |
Intervention |
Control |
Phase 1 |
ACTRN12622000713796p |
Post Partum Depression and Treatment Resistant Depression |
2022 |
Other |
Recruiting |
Ongoing |
Adelaide |
Field Trip |
32 |
Blinded |
FT-104 |
Normal Saline (0.9% sodium chloride) for injection |